These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 11440031

  • 1. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
    Tiling R, Linke R, Untch M, Richter A, Fieber S, Brinkbäumer K, Tatsch K, Hahn K.
    Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours.
    Palmedo H, Bender H, Grünwald F, Mallmann P, Zamora P, Krebs D, Biersack HJ.
    Eur J Nucl Med; 1997 Sep; 24(9):1138-45. PubMed ID: 9283107
    [Abstract] [Full Text] [Related]

  • 4. 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.
    Higashi K, Ueda Y, Matsunari I, Kodama Y, Ikeda R, Miura K, Taki S, Higuchi T, Tonami H, Yamamoto I.
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):13-21. PubMed ID: 14574513
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography.
    Tiling R, Kessler M, Untch M, Sommer H, Linke R, Brinkbäumer K, Hahn K.
    Onkologie; 2003 Feb; 26(1):27-31. PubMed ID: 12624514
    [Abstract] [Full Text] [Related]

  • 8. In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography.
    Mezi S, Primi F, Capoccetti F, Scopinaro F, Modesti M, Schillaci O.
    Int J Oncol; 2003 Jun; 22(6):1233-40. PubMed ID: 12738988
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Myocardial distribution of (18)F-FDG and (99m)Tc-sestamibi on dual-isotope simultaneous acquisition SPET compared with PET.
    Matsunari I, Kanayama S, Yoneyama T, Matsudaira M, Nakajima K, Taki J, Nekolla SG, Takekoshi N, Tonami N, Hisada K.
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1357-64. PubMed ID: 12271419
    [Abstract] [Full Text] [Related]

  • 12. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, Nakamoto Y, Higashi T, Saga T, Konishi J.
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [Abstract] [Full Text] [Related]

  • 13. [Breast scintigraphy using 99mTc-sestamibi--use and limitations].
    Tiling R, Linke R, Kessler M, Untch M, Sommer H, Brinkbäumer K, Becker I, Hahn K.
    Nuklearmedizin; 2002 Jun; 41(3):148-56. PubMed ID: 12109035
    [Abstract] [Full Text] [Related]

  • 14. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients.
    Sergieva SB, Timcheva KV, Hadjiolov ND.
    J BUON; 2006 Jun; 11(1):61-8. PubMed ID: 17318954
    [Abstract] [Full Text] [Related]

  • 15. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J, Tiling R, Avril-Sassen S, Mahner S, Lebeau A, Weber C, Schwaiger M, Jänicke F, Untch M, Avril N.
    Br J Cancer; 2010 Jan 05; 102(1):35-41. PubMed ID: 19920815
    [Abstract] [Full Text] [Related]

  • 16. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D, Chen JH, Wang J, Ling R, Yao Q, Wang L.
    Ai Zheng; 2007 Aug 05; 26(8):900-4. PubMed ID: 17697556
    [Abstract] [Full Text] [Related]

  • 17. Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis.
    Guo C, Zhang C, Liu J, Tong L, Huang G.
    Nucl Med Commun; 2016 Jul 05; 37(7):675-88. PubMed ID: 26974314
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.
    Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, Kirsch CM.
    Eur J Nucl Med; 1999 Feb 05; 26(2):144-51. PubMed ID: 9933348
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment evaluation of carcinomas of the hypopharynx and larynx with 18F-fluorodeoxyglucose, 123I-alpha-methyl-L-tyrosine and 99mTc-hexakis-2-methoxyisobutylisonitrile.
    Henze M, Mohammed A, Mier W, Rudat V, Dietz A, Nollert J, Eisenhut M, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2002 Mar 05; 29(3):324-30. PubMed ID: 12002706
    [Abstract] [Full Text] [Related]

  • 20. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
    Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA.
    Cancer; 2005 Feb 15; 103(4):680-8. PubMed ID: 15637688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.